Not long ago, the conversion of relapsing to secondary progressive multiple sclerosis (MS) marked the boundaries between treatable and non-treatable MS. This was generally accepted although some of the interferon-beta formulations, such as interferon beta-1b, and mitoxantrone were approved in some countries for secondary progressive MS with superimposed relapses. The injectables showed at best very moderate efficacy, and mitoxantrone was infrequently used due to its unfavorable safety profile. Only very recently, the second-generation sphingosine-1-phosphate modulator siponimod was approved in the United States based on a randomized controlled phase 3 study specifically assessing efficacy in active secondary progressive MS. 1 Clearly, when setting up a treatment plan in an individual with relapsing MS, multiple aspects need to be considered and undoubtedly, factors determining the risk to go on to develop the secondary progressive form of the disease are of paramount importance. Large registries help to identify factors conveying an increased risk to change from relapsing to secondary progressive MS. MSBase is a global enterprise under the stewardship of the Melbourne group that has collected more than 65,000 patient records from more than 130 centers in 35 countries.
In this issue of the journal, Fambiatos et al. 2 study the characteristics of patients with adult-onset relapsing MS that may influence the risk of conversion to a secondary progressive disease course. The data were derived from the MSBase cohort, and a time-dependent survival model was used analyzing the data of more than 15,000 patients. Several parameters associated with secondary progression in the study, such as older age, longer disease duration, or higher/rapidly increasing Expanded Disability Status Scale (EDSS) score, were rather trivial (as being part of the definition of conversion), 3 or not new. Some parameters generally considered to be linked to worsening disability, such as brain magnetic resonance imaging (MRI) activity and cerebrospinal fluid (CSF) oligoclonal bands, were unexpectedly not found to be associated with the risk of conversion to secondary progression, possibly related to data quality, or methodological issues. Of clinical relevance, the number of relapses in the preceding year, as well as the overall annualized relapse rate in patients with long-term follow-up (⩾9 years), predicted secondary progression. Relapse-driven EDSS score progression may explain such finding, supporting recent studies from MSBase that demonstrated beneficial effects of registered immune therapies for MS not only on relapse rate but also on EDSS score progression, and conversion to secondary progression. 4, 5 Overall, it clearly is an asset to have global postmarketing registries such as MSBase to inform on real-world efficiency, tolerability, side effects, and risks of interventions in MS, with broad generalizability. Nonetheless, analysis of big data requires a careful, pre-defined analysis plan, so that clinically relevant, yet unanswered, questions are addressed, and the messages sent are more than self-fulfilling prophecies. Furthermore, efforts are needed to increase data quality in such global databases, including classical study parameters, and also patient-related outcomes.
